In your interest.
Online Personal Finance Magazine
No beating about the bush.
Pharma continues to be in the limelight and is poised for more of it, thanks to Ranbaxy’s blockbuster deal with Daiichi of Japan. The market thinks that this takeover has set the stage for smaller companies, particularly those operating in contract research and the manufacturing arena, to be targets of such deals. One such stock is that of Divi’s Laboratories which naturally...
Poor supervision. That is the only explanation for a Business Standard report dated 11th June with the headline “Registration records show no real estate slowdown in M’rashtra” that blew up two-month-old statistics without examining their date and relevance. It claimed that, despite the ‘buzz’ about a slowdown, data on property registrations in five cities of Maharashtra showed 10.53% increase...
Indiscriminate panic selling broke the upward momentum in several stocks. We are making six changes.
The major gainers last fortnight were pharma companies following the Daiichi takeover of Ranbaxy. The biggest gainer among our momentum stocks was Nectar Lifesciences (20%), manufacturer of sterile and oral range of bulk drug antibiotics, even as the Sensex was down by over 1,200...